Skip to content
For National Public Health Week, the Biotechnology Innovation Organization (BIO) is talking to Deborah Levine, Director at the City of New York Graduate School […]
Community involvement is key to effective public health Read More »
The threat of expanding intellectual property waivers by the World Trade Organization (WTO) dampens investment in research, Biotechnology Innovation Organization’s (BIO) Chief Policy Officer
BIO opposes extension of WTO IP waiver in federal hearing Read More »
The lessons of COVID-19 were unequivocal: Pandemic preparedness is key to national security. According to a national poll conducted by the Biotechnology Innovation Organization
Voters want better pandemic preparedness Read More »
The impact of drug price controls on innovation, market distortions caused by pharmacy benefit managers (PBMs), and the importance of accelerated approval came up
House 2024 health budget hearings touch on price controls and PBMs Read More »
The Black Coalition Against COVID (BCAC) was born on Easter Sunday 2020. Dr. Reed Tuckson, the organization’s co-founder recalls, “We looked at the data
The Accelerated Approval pathway was established by the U.S. Food and Drug Administration (FDA) in the 1990s to boost R&D for HIV/AIDS, and the
I am BIO Podcast: Accelerated Approval, accelerating hope Read More »
According to a recent report from the Centers for Disease Control and Prevention (CDC), drug-resistant Candida auris (C. auris) fungus cases “spread at an
Drug-resistant C. auris fungi cases tripled in 2021 says CDC Read More »
The Department of Health and Human Services (HHS) and Department of Commerce (DOC) will investigate using Bayh-Dole march-in rights as a way to control
HHS investigating using Bayh-Dole march-in rights for price controls Read More »
The Senate Commerce Committee approved legislation yesterday which prohibits pharmacy benefit managers (PBMs) from pocketing the rebates they collect from drug makers. The bill
PBM Transparency Act now heads to full Senate Read More »
Government policy impacting biotech—including drug price controls, pharmacy benefit managers (PBMs), accelerated approval, and support for new antibiotics—received a public airing this week when
